When Raising Capital, CEOs Should Understand the LSN Value Proposition

By Skylar Jacobs, Business Development Manager, LSN

As Next Phase discussed two weeks ago, the world of early stage biotech and medtech investment is far less than straightforward and CEOs often have limited resources for learning where they fit into the capital landscape. In this article, we’ll look more closely at how LSN designed the LSN Investor Platform to address this problem.

Finding and Connecting with Investors that are a Fit for Your Company

LSN has found that the biggest difficulty for fundraising executives is identifying active investors that are a fit for their stage of development and product.  When raising a seed or series A financing, most executives go straight to a few brand name VCs and angel groups in their backyard, and, mistakenly, think this is going to get the job done. The reality is that fundraising is a numbers game, and there are thousands of groups across the world that are not currently known to the fundraising team, but may be a great fit for your venture. The problem is how to efficiently identify these groups, if they are a fit and, most importantly, how to reach them.

Global Matching Platform

Through this outreach, LSN has created the LSN Investor Database, giving fundraising executives the ability to generate a global target list of investors who are a fit for their company.  Like all databases, there is a front end of the active players – which is approximately half of our total network– which includes profiles of firms in active dialogue with the LSN Research Team and profiles of firms that have enough publicly available information/contact details to be listed.  The back-end of the database contains investors that have requested that LSN match them with fundraising companies but prefer not to be listed in the front end, investors we have identified but are not currently investing, and profiles that will be moved into the front end once we have enough data to justify value. The good news is that we think we have identified about 85% of the global early stage investors.  The functionality of the LSN Investor Database allows you to easily apply filters to generate a list of firms who are a fit for your company, which usually leaves about 300-500 firms as initial targets to begin initial qualification and potential interest.

Pricing

The LSN team has conducted an analysis of hundreds of successful fundraising campaigns and has determined that, on average, a start-up company can expect to spend between $70,000 to $100,000 on their fundraising efforts.  These costs include: creating and maintaining your marketing materials and web presence, business trips, conferences, partnering road trips and other miscellaneous costs.

Campaign Component
Typical Cost
Creating and maintaining your branding, messaging, marketing collateral and web presence for a year
$25,000 – $30,000
One conference per quarter, travel and expenses
$12,000 – $20,000
1-2 week road trip per quarter, two people
$10,000 – $15,000
Global target list of investors and campaign infrastructure
$10,000 – $12,000
Legal and professional fees
$10,000 – $20,000
TOTAL
$67,000 – $97,000

The LSN Investor Platform is competitively priced at $6,995 for an annual subscription to fundraising executives.  This pricing is based upon making you, the fundraiser, more effective and efficient by dramatically increasing your access to global investors that are a fit for your company’s stage of development and product. Pricing justification is that the annual subscription costs:

  • 10% of typical fundraising campaign costs
  • Approximately $25 per targeted investor profile

The LSN Research Team has done the work for you to collect details regarding exact investment interests, typical allocation size, fund vintage, company management team requirements, past investment history, and personal contact details for Partners, Directors, and C-Level Executives at each firm – information that is rarely found in other investor profiles. The price of the LSN Investor Database includes: initial identification of our client’s global target list of 300-500 investors, a consultation on your introductory marketing materials (intro email and deck), campaign outreach advice, and email alerts including updates of investors added to the platform who are a fit for your company.  Additionally, the LSN Investor Platform includes an export function that provides startup CEOs with data that can be imported into a CRM system to manage outreach and track the progress of every investor relationship.  LSN has already integrated with SalesForce.com to make this process seamless for our clients.  In total, LSN offers a complete package for fundraising executives to ensure they have the strategy and investor targets necessary to conduct a successful capital raise.

The Redefining Early Stage Investments Conference Series

In addition to the LSN Investor Platform, the RESI Conference is another tool provided by LSN for fundraising CEOs. The RESI conference allows entrepreneurs to meet face-to-face with up to 16 relevant investors in one day and begin to develop a personal relationship with them. Subscribers of the LSN Investor Platform have a powerful tool that allows them dig into the investors’ profile prior to the meeting to understand the investors’ interests and preferences, greatly increasing the quality of an intro discussion and making the best use of their face-time. Using the LSN Investor Platform and RESI conference in parallel creates a tremendous value for any fundraising CEO in the early-stage life science space by not only providing the connections, but also by facilitating face-to-face interactions.

In Summary

LSN estimates that approximately 250 clients who read our CEO’s book, The Life Science Executive’s Fundraising Manifesto, purchased the database, and participated in the RESI Conference Series have raised upwards of 350 million dollars.  LSN’s value add to a fundraising CEO and scientist/entrepreneur is equivalent to 5 years’ work by 6 LSN research analysts, curating your Global Target List (GTL), which is at least 50% of the effort of raising capital – finding investors that are a fit for your stage of development and product.

The personal connection between the LSN research team and an investment firm allows LSN to capture and utilize a unique flow of information and provides an unmatched tool for fundraising CEOs to understand the players in their space, their nuanced preferences/strategies and a way to begin a dialogue with them. No other service or data provider comes close to the focused, high touch, relationship-oriented nature of data collection and maintenance.

Hot Investor Mandate 1: Global VC Invests Up to $10M in Novel Software-Based Healthcare Technologies with Focus in North America

A venture capital firm with a global presence invests in several verticals with the core interest being in scalable, breakthrough technologies. Initial investments may range from $100k – $1M, with up to $10M being invested over the life of the investment, in the form of convertible notes or straight equity. The firm will lead investments or co-invest as a syndicate. The firm will invest in companies on a global basis but is focused on companies in the U.S. and Canada. The partners and advisors of the fund look to add value to portfolio companies through an extensive international network and strong technical expertise.

The firm is generally agnostic to industry and is most interested in unique/novel technologies, with a special interest in AI and blockchain solutions in the healthcare space. While the group is primarily interested in software-based technologies, whether in drug discovery, enterprise software, digital health, etc., medical devices that do not require a traditional regulatory pathway (510(k) or PMA) and that have a core software component will also be considered.

The firm has no strict company or management team requirements and looks to mentor companies/management teams. The firm does not require a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Venture Arm of Large Health Insurance Provider Invests Broadly in Medtech, Diagnostics, and Digital Health with Strong Strategic Value

A wholly-owned venture arm subsidiary of one of the largest health insurers makes strategic investments in healthcare-related innovations that will improve the quality of care and enhance the overall healthcare experience for consumers and providers. 3 important considerations are strategic value, financial return, and improvement in health outcomes. The firm typically participates in Series B or post-Series A bridge rounds. The firm entertains domestic and international opportunities.

The firm invests broadly across healthcare. Recent investments include a lung cancer diagnostics company, a specialty pharmacy company that simplifies medication management, and a behavioral health care management company. The firm expects companies to be past the proof-of-concept stage with demonstration of some traction.

The firm has no specific requirements and can work with all kinds of management teams. The firm is open to both leading and co-investing in financing rounds. The firm may take a board seat when applicable.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Life Sciences VC Arm of Large Czech Financial Group Seeks Early-Stage Investment Opportunities in All Sectors

An investment arm of a large, Czech Republic-based financial group that manages 10 sub-funds that total to $400M AUM, has a $22M fund through which the firm actively invests in early-stage life-science companies. The firm prefers to act as the first institutional investor – i.e. it deploys around $250 to $350,000 as initial investment and then provides follow-on investments for companies that achieve a number of milestones. The firm will consider opportunities globally, but mainly focuses its activities in North America and Europe.

The fund is sector agnostic and will consider all innovative technologies within the areas of therapeutics, medical devices, diagnostics, and healthcare IT. About 1/3 of the fund is dedicated to digital health technologies with special interest in the area of mental health. While the fund is mostly indication agnostic, it tends to avoid the over-crowded indications such as oncology/immune-oncology.

The firm is an active investor and takes a dedicated role in its portfolio of companies, providing them with resources and expertise to support company growth. The firm seeks to work with experienced management teams that are working on technology with strong market potential. The firm prefers to act as the lead investor but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Seed-Stage Venture Fund Invests in Ontario-Based Life Science Companies with Strongest Interest in Healthcare IT/Digital Health

A seed-stage venture capital fund that seeks to invest in Ontario-based companies operating in the cleantech, information and communication technology, life science and healthcare sectors. The firm is based out of Toronto, Canada and has been investing for over 10 years. The fund is sector-agnostic and invests in several verticals including but not limited to IT, healthcare, and cleantech. The fund makes investments up to $500K in Ontario-based startups, and typically targets 15 deals per year. The fund will invest with VCs and other institutional investors.

The fund is a generalist fund, but within the healthcare space, the focus is on healthcare IT and digital health companies whose core technology is software, whether it be enterprise solutions or more consumer-facing or point of care technologies. Traditional medical devices, biopharma/therapeutics and other life science platform technologies will be also be considered.

The firm requires the company be legally company incorporated and likes to see a formal management structure in place by the time of closing an investment. It’s not necessary that the company have revenues, but the company must have a clear understanding of their path to market and an execution strategy in place that will allow them to move faster than competitors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Relationship-Transactional-Based Conference: LSN’s Redefining Early Stage Investments Conference – What’s Different?

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

RESI takes place every few months and is a “rolling” ongoing conference series that provides a vehicle to regularly meet with potential partners. No other conference provider has instituted this kind of format. Most conferences are either annual or bi-annual. At RESI, the two main constituencies – scientist/entrepreneurs and investors/strategic partners – have an ongoing opportunity to connect based on fit (i.e. type of product, stage of company, size of raise and other criteria), create a dialogue that grows into a relationship and eventual partnership. LSN has found that having a conference series where buyer and seller can easily meet and follow up every few months greatly aids the building-a-relationship process.

The state of the partnering-conference model that LSN saw when we launched RESI was mostly content-based informational conferences with a partnering software program you could use to set up meetings.

LSN added a matching module for the pairing-up of profiles of the early stage buy-side and sell-side players. RESI is a relationship-based partnering conference and not a content-based informational conference. There is a huge difference in the two models. I recently wrote an article about the subject.

Partnerships take time to move down the tracks, and the RESI conference provides a one-of-a-kind vehicle: a series of ongoing meetings in various geographic life science hubs that has become an industry-wide vehicle to identify, meet and continue a dialogue with potential partners. For both the sell-side and the buy-side, establishing and consummating partnerships is a full-time job. RESI makes it easier for both sides. Scientist/entrepreneurs find investors/strategic partners and investors/strategic partners source technology assets.

Most life science conferences, even though some have partnering, are still information-centric: paid speakers, panels of industry trends and programming around providing information and education. RESI is relationship-based, so no paid speakers – as a matter of fact, investors vie for speaking spots because of the status that is associated with being on a panel at a RESI conference. Most conferences are silo specific – either drugs, devices, diagnostics or healthcare IT. RESI covers all these silos, and that’s a plus for investors and strategic partners whose mandates cut across several verticals.

RESI is purely partnering-based, and the content and panels revolve around the investors’ and the strategic partners’ existing mandates. RESI’s Workshops are all about helping with various start up issues: from valuations, to negotiating LOIs, to branding and messaging, to fundraising boot camps. No FDA, no BREXIT, no lending or debt, just very focused on connecting and navigating the early-stage arena. It’s all about learning and interacting with investors and strategic partners.

Canada is a Rising Power in Life Science Innovation

By Lucy Parkinson, Director of Research, LSN

RESI is headed to MaRS in Toronto for the third time. Our annual visits to the city have allowed LSN to take the pulse of Canadian life science, and we have seen Canada go from strength to strength over the years and attract an increasing amount of investment interest. Taking a look at a sample of startup data from the LSN Company Platform, we can examine life science trends in Canada.

While every region of Canada is home to some life science startup activity, the main hubs are in Ontario, Quebec and British Columbia. Let’s see how the different verticals within life science and health innovation are represented in those three hubs. From our sample, we took a look at early stage therapeutic companies (Preclinical through Phase II), development-stage medical technology companies, and all digital health companies.

While biotech activity is occurring throughout Canada, we see a concentration of digital health and medtech activity in Ontario. The city of Toronto is home to several major research universities and institutions, and innovation has grown up around this research hub.

Looking more closely at those early stage biotech assets, we find that Canada’s drug development startups have developed a strong base of preclinical assets and many of those assets have moved through to Phase I and Phase II.

Much like in other regions, oncology is the dominant area of research, but Canada is also home to a wealth of biotech development in neurology, infectious diseases, dermatology, and other fields.

It’s little wonder that investors are starting to look north of the border for life science deals. Taking a look into the LSN Investor Platform, we find that LSN tracks over 700 investors who will consider an investment opportunity in Canada. Over 80% of those investors are located outside of Canada! We anticipate that from those investment firms, over 300 investment staff will be in attendance at the upcoming RESI on MaRS event. As novel life science technology becomes an increasingly global marketplace, LSN encounters more investors who have a global rather than a regional mindset when it comes to finding high quality assets, and with so much research being generated by top institutions, Canada is well placed to take advantage of that trend.